Christophe Borg

机构：Centre Hospitalier Universitaire de Besançon, Methodology and Quality of Life Unit in Oncology, Université de Franche-Comté · ORCID：0000-0001-6161-0169

发表论文 459 篇 · 总被引 20784 次 · h-index 58

代表论文

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 698)
• Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 531)
• Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial (2024 · Annals of Oncology · 被引 229)
• Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study (2024 · The Lancet Oncology · 被引 27)
• Early ctDNA and Survival in Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors (2025 · JAMA Oncology · 被引 26)
• Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study (2023 · British Journal of Cancer · 被引 17)